ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

MTNB Matinas Biopharma Holdings Inc

0.1756
-0.0011 (-0.62%)
10 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Matinas Biopharma Holdings Inc MTNB AMEX Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.0011 -0.62% 0.1756 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.1767 0.1673 0.177 0.1756 0.1767
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
09/5/202415:06EDGAR2Form 8-K - Current report
09/5/202415:05GLOBEMatinas BioPharma Reports First Quarter 2024 Financial..
09/5/202415:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202407:00GLOBEMatinas BioPharma’s LNC Platform for the Delivery of Small..
02/5/202406:00GLOBEMatinas BioPharma to Webcast Conference Call to Discuss..
30/4/202407:00GLOBEIn Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in..
03/4/202407:30GLOBEMatinas BioPharma Prices $10 Million Registered Direct..
27/3/202415:05GLOBEMatinas BioPharma Reports 2023 Financial Results and..
25/3/202407:00GLOBEMatinas BioPharma Announces Positive in vivo Safety Data..
22/3/202408:15GLOBEThree Patients with Invasive Fusarium Infection in Matinas..
22/3/202405:30GLOBEMatinas BioPharma Regains Compliance with NYSE American..
26/2/202407:05EDGAR2Form 8-K - Current report
26/2/202407:00GLOBEMatinas BioPharma Provides Positive Outcomes Update on the..
20/2/202406:35EDGAR2Form 8-K - Current report
20/2/202406:30GLOBEMatinas BioPharma Successfully Reaches Agreement with FDA..
09/1/202406:30EDGAR2Form 8-K - Current report
03/1/202406:00GLOBEMatinas BioPharma to Present at Biotech Showcase 2024
27/12/202306:40EDGAR2Form 8-K - Current report
27/12/202306:30GLOBEMatinas BioPharma Demonstrates in vivo Biological Activity..
21/12/202306:40EDGAR2Form 8-K - Current report
21/12/202306:30GLOBEMatinas BioPharma Provides Update to MAT2203 Regulatory and..
15/12/202320:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202320:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202320:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202320:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202320:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202320:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/11/202306:30EDGAR2Form 8-K - Current report
09/11/202316:25EDGAR2Form 8-K - Current report
08/11/202315:06EDGAR2Form 8-K - Current report
08/11/202315:05GLOBEMatinas BioPharma Reports Third Quarter 2023 Financial..
08/11/202315:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202306:30GLOBEMatinas BioPharma Announces Positive in vivo Efficacy..
03/11/202315:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202316:20EDGAR2Form 8-K - Current report
01/11/202306:00GLOBEMatinas BioPharma to Webcast Conference Call to Discuss..
11/10/202309:25APSBiotech Catches Massive Premarket Bid
11/10/202306:30GLOBEPatient with Candida krusei Infection in Matinas BioPharma’s..
28/9/202306:00GLOBEMatinas BioPharma to Present at Two Investment Conferences..
27/9/202306:00GLOBEMatinas BioPharma to Feature MAT2203 in a Pipeline..
22/9/202316:25EDGAR2Form 8-K - Current report
22/9/202316:25GLOBEMatinas BioPharma Announces Notification of NYSE American..
21/9/202308:35GLOBEDawson James Securities Announces October Date for 8th..
20/9/202306:30EDGAR2Form 8-K - Current report
19/9/202316:25EDGAR2Form DEF 14A - Other definitive proxy statements
08/9/202316:15EDGAR2Form PRE 14A - Other preliminary proxy statements
06/9/202306:00GLOBEMatinas BioPharma to Participate in the H.C. Wainwright..
22/8/202306:30GLOBEMatinas BioPharma Announces Publication of Results from the..
09/8/202315:06EDGAR2Form 8-K - Current report
09/8/202315:05GLOBEMatinas BioPharma Reports Second Quarter 2023 Financial..

Su Consulta Reciente

Delayed Upgrade Clock